SCHEMBL1978257

SCHEMBL1978257

COCCOc1ccn2c(-c3ccc4cccc(N5CCNCC5)c4n3)nnc2c1

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.52
FLT3 P36888 4/20 0.52
KIT P10721 3/20 0.52
PIM1 P11309 5/20 0.51
PIM2 Q9P1W9 4/20 0.51
CSF1R P07333 10/20 0.50
CYP2D6 P10635 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1977205 0.89 PIM1 (0.52) PIM1PIM2
SCHEMBL3334532 0.86 KDR (0.70) KDRFLT3KITCSF1RCYP2D6
SCHEMBL1975295 0.84 KDR (0.44) KDRFLT3KITPIM1PIM2
SCHEMBL1967379 0.81 KDR (0.52) KDRFLT3KITPIM1PIM2
SCHEMBL1966171 0.80 PIM1 (0.79) KDRPIM1PIM2CSF1R
Hydrochloric Acid SCHEMBL1975274 0.80 PIM1 (0.78) KDRPIM1PIM2CSF1R
SCHEMBL1976974 0.78 PIM1 (0.52) PIM1PIM2
SCHEMBL3329975 0.78 KDR (0.71) KDRFLT3KITCSF1RCYP2D6
SCHEMBL1976027 0.78 PIM1 (0.73) PIM1PIM2
SCHEMBL3331332 0.78 KDR (0.67) KDRFLT3KITCSF1RCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895550-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-25 US disclosed
US-8895550-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-25 US disclosed
US-20140045835-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-20140045835-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-8557809-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-15 US disclosed
US-8557809-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-15 US disclosed
US-20110144100-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
US-20110144100-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
WO-2010022081-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045835-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 KDR 589/4885FLT3 54/4885KIT 163/4885
US-20110144100-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM3, PIM2 KDR 94/4885FLT3 6/4885KIT 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.